Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Gazzard

Showing results (111-120 of 206) with videos related to

Pageof 21
Sort By:
British Journal of Pharmacology|January 26, 2019
Pharmacological impact of antiretroviral therapy on platelet function to investigate human immunodeficiency virus-associated cardiovascular riskKirk A Taylor, Erica Smyth, Francesca Rauzi, et al.
The Journal of Antimicrobial Chemotherapy|September 21, 2006
Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patientsJennifer Ford, Marta Boffito, Desmond Maitland, et al.
Cell Research|July 1, 2004
Studies on the allostimulatory function of dendritic cells from HCV-HIV-1 co-infected patientsJustin Stebbing, Steve Patterson, Simon Portsmouth, et al.
The Journal of Antimicrobial Chemotherapy|February 22, 2005
Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100 mg once daily versus twice dailyMarta Boffito, Desmond Maitland, Laura Dickinson, et al.
The Journal of Antimicrobial Chemotherapy|December 21, 2004
A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study)Chloe Orkin, Justin Stebbing, Mark Nelson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 11, 2009
Cryptogenic pseudocirrhosis: a new clinical syndrome of noncirrhotic portal hypertension (unassociated with advanced fibrosis) that can be detected by transient elastography in patients with HIVGeorge Panos, Lavanta Farouk, Justin Stebbing, et al.
Blood|January 4, 2008
Immunologic recovery in survivors following chemotherapy for AIDS-related non-Hodgkin lymphomaMark Bower, Justin Stebbing, Mark Tuthill, et al.
Antiviral Therapy|January 24, 2012
Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjectsAkil Jackson, Graeme Moyle, Laura Dickinson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 22, 2009
Pharmacokinetics and safety of etravirine administered once or twice daily after 2 weeks treatment with efavirenz in healthy volunteersMarta Boffito, Akil Jackson, Mohammed Lamorde, et al.
Antimicrobial Agents and Chemotherapy|June 25, 2004
Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patientsJennifer Ford, Marta Boffito, Adrian Wildfire, et al.
Pageof 21

Showing results (111-120 of 206) with videos related to

Sort By:
Pageof 21
British Journal of Pharmacology|January 26, 2019
Pharmacological impact of antiretroviral therapy on platelet function to investigate human immunodeficiency virus-associated cardiovascular riskKirk A Taylor, Erica Smyth, Francesca Rauzi, et al.
The Journal of Antimicrobial Chemotherapy|September 21, 2006
Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patientsJennifer Ford, Marta Boffito, Desmond Maitland, et al.
Cell Research|July 1, 2004
Studies on the allostimulatory function of dendritic cells from HCV-HIV-1 co-infected patientsJustin Stebbing, Steve Patterson, Simon Portsmouth, et al.
The Journal of Antimicrobial Chemotherapy|February 22, 2005
Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100 mg once daily versus twice dailyMarta Boffito, Desmond Maitland, Laura Dickinson, et al.
The Journal of Antimicrobial Chemotherapy|December 21, 2004
A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study)Chloe Orkin, Justin Stebbing, Mark Nelson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 11, 2009
Cryptogenic pseudocirrhosis: a new clinical syndrome of noncirrhotic portal hypertension (unassociated with advanced fibrosis) that can be detected by transient elastography in patients with HIVGeorge Panos, Lavanta Farouk, Justin Stebbing, et al.
Blood|January 4, 2008
Immunologic recovery in survivors following chemotherapy for AIDS-related non-Hodgkin lymphomaMark Bower, Justin Stebbing, Mark Tuthill, et al.
Antiviral Therapy|January 24, 2012
Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjectsAkil Jackson, Graeme Moyle, Laura Dickinson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 22, 2009
Pharmacokinetics and safety of etravirine administered once or twice daily after 2 weeks treatment with efavirenz in healthy volunteersMarta Boffito, Akil Jackson, Mohammed Lamorde, et al.
Antimicrobial Agents and Chemotherapy|June 25, 2004
Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patientsJennifer Ford, Marta Boffito, Adrian Wildfire, et al.
Pageof 21